21:07 , Jun 13, 2019 |  BC Innovations  |  Product Development

Why BioMarin took gene therapy manufacturing into its own hands

As gene therapy companies fight for space at contract manufacturers, BioMarin has leveraged its expertise in biologics to design its own capabilities for manufacturing gene therapies and gain control of the process -- a move...
03:11 , Jun 7, 2019 |  BC Extra  |  Company News

Exonics takeout, expanded CRISPR deal vault Vertex into neuromuscular diseases

Via a pair of deals totaling $420 million in upfront payments late Thursday, Vertex expanded into neuromuscular diseases and bolstered its gene editing capabilities by acquiring Exonics, broadening its partnership with CRISPR Therapeutics and hiring...
21:53 , May 29, 2019 |  BC Extra  |  Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
23:01 , May 2, 2019 |  BC Week In Review  |  Clinical News

Modest differences in outcomes for doses of Audentes myopathy gene therapy

Audentes presented updated data from the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy (XLMTM) showing that the trial's low and high doses had comparable safety and efficacy profiles. Chairman and CEO...
22:42 , Apr 8, 2019 |  BC Extra  |  Company News

Audentes to develop vectorized antisense therapies with Nationwide

Audentes partnered with Nationwide Children's Hospital to develop antisense oligonucleotides delivered with the biotech's adeno-associated viral (AAV) vectors to treat muscular dystrophies. Audentes Therapeutics Inc. (NASDAQ:BOLD) Chairman and CEO Matt Patterson told BioCentury the decision...
22:42 , Apr 1, 2019 |  BC Extra  |  Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
03:55 , Dec 14, 2018 |  BC Innovations  |  Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
00:05 , Nov 6, 2018 |  BC Extra  |  Company News

Management tracks: Audentes, Veloxis

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) appointed CEO and co-founder Matthew Patterson as chairman. Patterson has been a board member since 2012. Audentes also appointed board member Louis Lange as lead independent director. Lange...
18:18 , Oct 12, 2018 |  BC Week In Review  |  Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million on Oct. 10 through the sale of 5.2 million shares at $29 in a follow-on underwritten by...